financetom
Business
financetom
/
Business
/
HCI Equity Partners Announces Agreement to Sell SDS Rx to DHL Supply Chain
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
HCI Equity Partners Announces Agreement to Sell SDS Rx to DHL Supply Chain
Sep 10, 2025 4:16 AM

Transaction positions SDS Rx to continue delivering patient-centric, final-mile healthcare logistics under the ownership of a global leaderWASHINGTON, Sept. 10, 2025 /PRNewswire/ -- HCI Equity Partners ("HCI"), a lower middle market private equity firm, today announced that its portfolio company Strategic Delivery Solutions, LLC ("SDS Rx") has entered into a definitive agreement to be acquired by DHL Supply Chain, a business unit of DHL Group. Terms of the transaction were not disclosed. Closing is expected to occur by the end of 2025 and is subject to customary conditions and approvals.

SDS Rx is a leading final-mile logistics and specialty healthcare transportation provider serving long-term care and specialty pharmacies, radiopharmacies, and health system networks across the United States. The company specializes in high-touch, time-critical deliveries that support quality of care for patients and providers.

"We are genuinely excited about the future of SDS under DHL's ownership. This is a fantastic home for the business, and we're confident SDS will thrive and accelerate realization of its exciting growth opportunities. HCI would like to thank the SDS leadership team and employees for their outstanding dedication and partnership during our ownership. Their hard work and commitment to excellence have been instrumental in positioning the company for this next chapter," said Doug McCormick, Managing Partner at HCI Equity Partners.

Why HCI Believes DHL Is the Right Home for SDS Rx:

Strategic fit: From HCI's perspective, SDS Rx's specialty final-mile expertise complements DHL's extensive life sciences and healthcare logistics platform, together offering broader solutions across the healthcare value chain.Customer focus: HCI believes DHL's scale and capabilities provide an excellent foundation to support SDS Rx's long-standing mission of patient-first service, ensuring customers continue to receive high-quality, reliable deliveries.People and operations: HCI is confident the combination offers continuity for SDS Rx employees and leadership, providing the resources of a global organization while preserving the strengths of the local teams that have driven the SDS's success.About SDS Rx

SDS Rx provides final-mile delivery and specialty healthcare transportation services to long-term care and specialty pharmacies, radiopharmacies, and health system networks, with operations spanning more than 200 locations in the United States and capabilities that include same-day and expedited delivery.

About HCI Equity Partners

HCI Equity Partners is a private equity firm focused on investing in lower middle market companies and building scaled industry leaders in large, stable, fragmented end markets through organic initiatives and strategic M&A. The firm partners with management teams in sectors such as distribution, technician-based services, and basic manufacturing to drive sustainable value creation. For more information, visit www.hciequity.com.

Forward-Looking Statements

This press release may contain "forward-looking statements," including statements regarding the expected timing and completion of the transaction, integration plans, and future operations and performance. Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. HCI undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this release.

Media Contact

Lambert by LLYC

Caroline Luz, [email protected], 203-570-6462

View original content:https://www.prnewswire.com/news-releases/hci-equity-partners-announces-agreement-to-sell-sds-rx-to-dhl-supply-chain-302552371.html

SOURCE HCI Equity Partners

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GSK Says Osteosarcoma Drug Candidate Receives FDA Breakthrough Therapy Designation
GSK Says Osteosarcoma Drug Candidate Receives FDA Breakthrough Therapy Designation
Jan 7, 2025
11:07 AM EST, 01/07/2025 (MT Newswires) -- GSK (GSK) said Tuesday that its investigational drug GSK5764227 for relapsed or refractory osteosarcoma has received Breakthrough Therapy Designation from the US Food and Drug Administration. The designation is supported by data from a phase 2 trial conducted by Hansoh Pharma, GSK said, adding it acquired exclusive worldwide rights from Hansoh Pharma last...
Point72 kicks off new private credit strategy, statement shows
Point72 kicks off new private credit strategy, statement shows
Jan 7, 2025
NEW YORK, Jan 7 (Reuters) - Point72 Asset Management has hired Todd Hirsch, a former senior managing director at Blackstone, to head a new strategy focused on the fast-growing private credit business, according to an internal statement seen by Reuters. Steve Cohen, the firm's founder, said in the statement that demand for private credit continues to exceed supply, creating a...
Nvidia's AI Leadership Extends Beyond Cloud, BofA Securities Says
Nvidia's AI Leadership Extends Beyond Cloud, BofA Securities Says
Jan 7, 2025
11:09 AM EST, 01/07/2025 (MT Newswires) -- Nvidia ( NVDA ) remains a leader in artificial intelligence across hardware and software and is expanding its influence beyond cloud services to enterprise and consumer markets, BofA Securities said in a note Tuesday. The company's Blackwell accelerators are now in full production and support over 200 configurations across major service providers positioning...
OPKO Health's ModeX Launches Phase 1 EBV Vaccine Candidate Trials With Merck
OPKO Health's ModeX Launches Phase 1 EBV Vaccine Candidate Trials With Merck
Jan 7, 2025
11:09 AM EST, 01/07/2025 (MT Newswires) -- OPKO Health's ( OPK ) ModeX Therapeutics subsidiary launched phase 1 clinical trials for an Epstein-Barr virus vaccine candidate in partnership with Merck ( MRK ) . The first participant was dosed in the MDX2201 study, which will assess safety and tolerability in up to 200 healthy adults, ModeX said Tuesday in a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved